A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
Launched by HOFFMANN-LA ROCHE · Sep 28, 2015
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults 18 to 75 years of age
- • Advanced and/or metastatic gastric cancer with at least 1 measurable lesion
- Exclusion Criteria:
- • Uncontrolled infection
- • Evidence of central nervous system (CNS) metastases
- • History of other malignancy within the last 5 years, except cured basal cell cancer of the skin or cured in-situ cancer of the uterine cervix
- • Radiation therapy or major surgery within 4 weeks of study drug
- • Previous chemotherapy
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Buenos Aires, , Argentina
Porto Alegre, , Brazil
Sorocaba, , Brazil
Beijing, , China
Shanghai, , China
Mexico City, , Mexico
Kazan, , Russian Federation
Moscow, , Russian Federation
St Petersburg, , Russian Federation
Ufa, , Russian Federation
Seoul, , Korea, Republic Of
Jiangsu, , China
Jiangxi, , China
Shandong, , China
Tianjin, , China
Guatemala City, , Guatemala
Bogota, , Colombia
Panama City, , Panama
Beijing, , China
Rosario, , Argentina
Hong Kong, , Hong Kong
Lima, , Peru
Callao, , Peru
Montevideo, , Uruguay
Shanghai, , China
Fortaleza, , Brazil
Sao Paulo, , Brazil
Suzhou, , China
Seoul, , Korea, Republic Of
Merida, , Mexico
Kuala Lumpur, , Malaysia
Hubei, , China
Tegucigalpa, , Belize
Barretos, , Brazil
Curitiba, , Brazil
Florianopolis, , Brazil
Guangdong, , China
Mexico Df, , Mexico
Patients applied
Trial Officials
Clinical Trials
Study Chair
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials